Synarc -- Biography

Home \| Contact Us \| Careers \| Site Index

Medical Imaging

Biochemical Markers

Clinical Research Centers

About CCBR-Synarc

CCBR-Synarc Experts

News & Events





	Back


		Anwar R. Padhani, M.D., Ph.D. Associate Medical Director, Oncology

Dr. Anwar R. Padhani is Associate Medical Director of Oncology at CCBR-Synarc. He is an internationally recognized oncological/MRI radiologist and currently the clinical lead in MRI and head of imaging research at the Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, London.

Dr. Padhani qualified in medicine at Kasturba Medical College, India in 1985. After studying general medicine at Cambridge, he undertook 5 years of radiological training (Addenbrooke’s Hospital, Cambridge; Guys Hospital, London; and John Hopkins Hospital, Baltimore, USA). Dr. Padhani was on the faculty of the Institute of Cancer Research, London as the CRC senior lecturer and held an honorary consultant radiologist position at the Royal Marsden Hospital, London for 6 years (1994-2000).

He was involved in the development of innovative research programs investigating functional MRI on the microenvironment of human tumors, and has performed numerous clinical research studies evaluating tumor perfusion, permeability, hypoxia and water diffusion imaging of breast, brain, rectal and prostate cancers as well as MRI studies of antiangiogenic and antivascular treatments.

Dr. Padhani has published chapters in 20 textbooks, 35 journal reviews, and published over 47 scientific articles in peer reviewed journals. Dr Padhani has given over 70 invited lectures at national and international meetings including plenary talks on angiogenesis and hypoxia imaging. He is deputy editor of the British Journal of Radiology and has co-edited the book “Advances in Oncologic Imaging Techniques” (Taylor & Francis, New York). He has also edited the “Guidelines for cross-sectional imaging in cancer management” (Royal College of Radiologist, UK).

Dr. Anwar R. Padhani can be reached by phone at +44.1923.844.751 and email at Anwar.Padhani@Synarc.com

Scientific Publications since 2003:

1: Lankester KJ, Taylor NJ, Stirling JJ, Boxall J, D'Arcy JA, Leach MO, Rustin GJ, Padhani AR. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer. 2005 Oct 31;93(9):979-85.

2: O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.

3: Beresford M, Padhani AR, Goh V, Makris A. Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther. 2005 Oct;5(5):893-905.

4: Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk
A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 25; [Epub ahead of print]

5: Warren RM, Pointon L, Thompson D, Hoff R, Gilbert FJ, Padhani A, Easton D,
Lakhani SR, Leach MO; UK Magnetic Resonance Imaging in Breast Screening (MARIBS)
Study Group. Reading protocol for dynamic contrast-enhanced MR images of the breast:
sensitivity and specificity analysis. Radiology. 2005 Sep;236(3):779-88.

6: Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ,
Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR,
Pointon LJ, Thompson D, Warren RM; MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005 May 21-27;365(9473):1769-78.

7: Jackson AS, Parker CC, Norman AR, Padhani AR, Huddart RA, Horwich A, Husband
JE, Dearnaley DP. Tumour staging using magnetic resonance imaging in clinically localised
prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen
deprivation and radical radiotherapy. Clin Oncol (R Coll Radiol). 2005 May;17(3):167-71.

8: Padhani AR, Ah-See ML, Makris A. MRI in the detection and management of breast cancer.
Expert Rev Anticancer Ther. 2005 Apr;5(2):239-52.

9: Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug
Development Office, Cancer Research UK. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005 May 9;92(9):1599-610.

10: Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging. 2005 May-Jun;30(3):324-41.

11: Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag. 2004 Sep-Oct;23(5):65-83.